NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
06 sept. 2024 16h03 HE
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs
06 sept. 2024 06h48 HE
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering....
Turkey Cancer Drugs Clinical Trials Market Research 2024 Featuring OMEGA CRO, mediSMART, CRM-CRO, CROTURK, and Klinar CRO
05 sept. 2024 04h21 HE
|
Research and Markets
Dublin, Sept. 05, 2024 (GLOBE NEWSWIRE) -- The "Turkey Cancer Drugs Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. Turkey presents an expanding...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
04 sept. 2024 16h15 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Down Syndrome Clinical Trials Review, 2024: Key Trends, Leading Companies, Latest Developments - Create Effective Counter Strategies to Gain a Competitive Advantage
04 sept. 2024 10h42 HE
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Down Syndrome - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report offers a...
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
04 sept. 2024 08h30 HE
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall is widely regarded as the...
Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
04 sept. 2024 07h30 HE
|
Jnana Therapeutics, Inc.
Jnana Therapeutics presents new positive data at SSIEM 2024 from Phase 1/2 study of JNT-517 in individuals with phenylketonuria (PKU).
CenExel iResearch and CenExel ACMR Unveil Dedicated PET Scan Unit for Specialized Research
03 sept. 2024 09h00 HE
|
CenExel Clinical Research
Atlanta, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- CenExel iResearch and CenExel ACMR, two premier Centers of Excellence located in Atlanta, Georgia, are thrilled to announce the launch of a dedicated...
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31 août 2024 03h54 HE
|
George Medicines
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
28 août 2024 01h15 HE
|
Novartis Pharma AG
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C reduction1 Results add to growing body of...